Extended Data Table 2 Patient Global Impression of Change (PGIC) at week 24

From: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

  1. At week 24, 177 patients in the pelabresib plus ruxolitinib arm and 194 patients in the placebo plus ruxolitinib arm had non-missing results; percentages are calculated based on patients with non-missing results.
Back to article page